Drugs / BMS-813160
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03496662 | Aug 2018 → Oct 2021 | pancreatic ductal adenocarcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT03184870 | Aug 2017 → Apr 2023 | colorectal cancer, malignant pancreatic neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04123379 | Mar 2020 → Aug 2023 overdue | hepatocellular carcinoma, non-small cell lung carcinoma | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02996110 | Feb 2017 → Nov 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01752985 | Mar 2013 → Jun 2015 | diabetic kidney disease | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01049165 Comparator | Feb → Nov 2010 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-813160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01752985 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 5 antagonist” CHEMBL4594419 ↗1“BMS-813160, a CCR2/5 dual antagonist” PMID 41571299 ↗ Jan 2026 |
| Modality | Small molecule | — CHEMBL4594419 ↗ |
| Route | Oral | “Oral Solution, Oral, 5 mg, Single dose, 1 day” NCT01049165 ↗ |
| Target | CCR2 | “BMS-813160 (CCR2/5 Inhibitor)” NCT03496662 ↗ |
| Target | CCR5 | “C-C chemokine receptor type 5 antagonist” CHEMBL4594419 ↗ |